Ida Holst Bekker-Jensen

Biochemistry, Biotechnology, Cancer Biology, Epigenetics, Immunology, Molecular Biology, Organic Chemistry

Partner / European Patent Attorney

Education: M.Sc (Biochemistry), University of Copenhagen, Ph.D. (Molecular Biology), University of Copenhagen

Technical expertise: Biochemistry, Organic chemistry, Molecular Biology, Epigenetics, Immunology and Cancer Biology

General Background: European Patent Attorney. With Budde Schou A/S since 2016.

IP qualifications: Expert advice, assistance and prosecution in relation to applications for patent, utility model and supplementary protection certificate (SPC) worldwide.

Memberships: ADIPA (Association of Danish Intellectual Property Attorneys), FIR (Danish Association for the Protection of Intellectual Property), EPI

Languages: Danish and English


    1. “Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.” Wu X, Bekker-Jensen IH, Christiensen J, Rasmussen KD, Sidoli S, Qi Y, Kong Y, Wang X, Cui Y, Xiao Z, Xu G, Williams K, Rappsilber J, Sønderby CK, Wither O, Jensen ON, Helin K. Cell Res. 2015 Nov;25(11):1205-18

    2. “Vascular endothelial growth factor receptor-3 expression in mycosis fungoides.” Pedersen IH, Willerslev-Olsen A, Vetter-Kauczok C, Krejsgaard T, Lauenborg B, Kopp KL, Geisler C, Bonefeld CM, Zhang Q, Wasik MA, Dabelsteen S, Woetmann A, Becker JC, Odum N. Leuk Lymphoma. 2013 Apr; 54(4):819-26